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ABSTRACT
Objectives Although cardiovascular disease (CVD) is a 
common comorbidity associated with chronic obstructive 
pulmonary disease (COPD), it is unknown how to improve 
prediction of cardiovascular (CV) risk in individuals with 
COPD. Traditional CV risk scores have been tested in 
different populations but not uniquely in COPD. The 
potential of alternative markers to improve CV risk 
prediction in individuals with COPD is unknown. We aimed 
to determine the predictive value of conventional CVD risk 
factors in COPD and to determine if additional markers 
improve prediction beyond conventional factors.
Design Data from the Evaluation of the Role of 
Inflammation in Chronic Airways disease cohort, which 
enrolled 729 individuals with Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) stage II–IV COPD were 
used. Linked hospital episode statistics and survival data 
were prospectively collected for a median 4.6 years of 
follow- up.
Setting Five UK centres interested in COPD.
Participants Population- based sample including 714 
individuals with spirometry- defined COPD, smoked at 
least 10 pack years and who were clinically stable for >4 
weeks.
Interventions Baseline measurements included aortic 
pulse wave velocity (aPWV), carotid intima–media 
thickness (CIMT), C reactive protein (CRP), fibrinogen, 
spirometry and Body mass index, airflow Obstruction, 
Dyspnoea and Exercise capacity (BODE) Index, 6 min walk 
test (6MWT) and 4 m gait speed (4MGS) test.
Primary and secondary outcome measures New 
occurrence (first event) of fatal or non- fatal hospitalised 
CVD, and all- cause and cause- specific mortality.
Results Out of 714 participants, 192 (27%) had CV 
hospitalisation and 6 died due to CVD. The overall CV risk 
model C- statistic was 0.689 (95% CI 0.688 to 0.691). aPWV 
and CIMT neither had an association with study outcome 
nor improved model prediction. CRP, fibrinogen, GOLD 
stage, BODE Index, 4MGS and 6MWT were associated with 
the outcome, independently of conventional risk factors 
(p<0.05 for all). However, only 6MWT improved model 
discrimination (C=0.727, 95% CI 0.726 to 0.728).
Conclusion Poor physical performance defined by 
the 6MWT improves prediction of CV hospitalisation in 
individuals with COPD.
Trial registration number ID 11101.
INTRODUCTION
Chronic obstructive pulmonary disease 
(COPD) is associated with a twofold to three-
fold increased risk of coronary artery disease 
and other cardiovascular (CV) comorbid-
ities.1 2 COPD and cardiovascular disease 
(CVD) are common conditions that share 
important common risk factors, such as 
smoking and physical inactivity, and both 
tend to affect older people. In addition, 
Strengths and limitations of this study
 ► This is the first study assessing the utility of conven-
tional cardiovascular (CV) disease risk factors for CV 
risk prediction and the value of additional markers of 
risk within a chronic obstructive pulmonary disease 
(COPD) cohort.
 ► Patient- level cohort data were linked to hospital 
admission data (ie, hospital episode statistics) ob-
tained from the National Health Services in England, 
Scotland and Wales, and Office for National Statistics 
record of mortality with analyses limited to 5 years 
of follow- up.
 ► Hospitalised CV episodes were coded based on 
International Statistical Classification of Diseases 
and Related Health Problems, 10th Revision, classi-
fications extracted from both primary and secondary 
positions.
 ► A multivariable prediction model, with 10- fold cross 
validation and 200 replications, was used to evalu-
ate a wide range of CV and physical performance 
biomarkers.
 ► Generalisability of our results is limited to those with 
moderate COPD in the UK with NHS hospitalisations.  on D
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both conditions are often associated with raised systemic 
inflammatory markers and increased arterial stiffness.3 4
Given the global healthcare burden associated with 
CVD,5 there is incentive to improve the accuracy of CV 
risk prediction in different populations. Individuals 
with COPD may be considered constitutively at high CV 
risk, given their age and smoking history. However, it is 
unknown whether classic CV risk prediction models, such 
as the Framingham General CV Risk score, which predicts 
an individual’s 10- year risk of developing CVD based on 
an algorithm of weighted risk factors and has been tested 
in a number of different populations,6–9 perform well in 
individuals with COPD.10 11
Conceptually, the performance of the Framingham 
model might be improved by additional measures. Candi-
date measurements include surrogate CV risk markers 
that impart mechanistic information (ie, aortic pulse 
wave velocity (aPWV) or carotid intima–media thick-
ness (CIMT)), inflammatory markers (ie, C reactive 
protein (CRP)) or measures of physical performance that 
enhance CV risk prediction in individuals with COPD. 
In fact, the value of these measures in CV risk predic-
tion have been explored in different population groups. 
For example, the 6 min walk test (6MWT) significantly 
improved risk prediction in patients with stable coronary 
disease.12 In individuals with intermediate CV risk but 
without CVD, adding CRP or fibrinogen to conventional 
risk factors modestly improved CV event prediction.13 A 
meta- analysis of aPWV studied in different disease cohorts 
showed it improved CV event prediction independently 
of conventional risk factors.14 In contrast, CIMT measure-
ment, although associated with CV risk factors, did not 
significantly improve risk prediction beyond traditional 
factors in individuals with hypertension.15 Given that indi-
viduals with COPD, in addition to having high CV risk 
based on conventional factors, also have increased aPWV, 
CIMT4 and increased inflammatory markers,16 as well as 
reduced lung function, which is associated with increased 
CV risk in the general population17 and reduced physical 
performance,18 19 the clinical significance of these find-
ings in relation to CV risk prediction in individuals with 
COPD is an important question to address.
The aims of our study were to first determine the predic-
tive value of conventional CVD risk factors for CV risk, 
defined by new occurrence (first event since study enrol-
ment) of fatal or non- fatal hospitalised CVD in individ-
uals with stable Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) stage II–IV20 COPD. A secondary 
aim was to determine whether addition of alternative CV 
measures (ie, aPWV and CIMT), inflammatory markers 
(ie, CRP and fibrinogen), COPD severity (ie, GOLD 
stage and Body mass index (BMI), airflow Obstruction, 
Dyspnoea and Exercise capacity (BODE) Index), as 
well as physical performance tests commonly used in 
COPD research (ie, 6MWT and 4 m gait speed (4MGS)) 
improved the predictive value of a CV risk model based on 
conventional CVD risk factors for CV risk prediction. We 
addressed these questions in the Evaluation of the Role of 
Inflammation in Chronic Airways disease (ERICA) COPD 
cohort using study data and linked UK electronic health 
records.
METHODS
Study design and participants
The ERICA study is a multicentre, observational cohort 
study with 729 individuals with stable GOLD stage II–IV20 
COPD, established to identify important CV and phys-
ical performance biomarkers that could be targeted to 
improve the outcomes of individuals with COPD. Partic-
ipants had a clinical diagnosis of COPD, smoking history 
of at least 10 pack years, postbronchodilator forced expi-
ratory lung volume in one second (FEV1)/forced vital 
capacity ratio of <0.7 and FEV1 ≤80% of predicted normal 
lung function, and were aged >40 years old and clinically 
stable for >4 weeks. Full details of the protocol have been 
provided elsewhere.21 Baseline data captured included 
demographics, spirometry, blood circulating biochem-
ical markers, measures of arterial stiffness (ie, aPWV and 
Augmentation Index (AIx)), CIMT and physical perfor-
mance (ie, 4MGS and 6MWT). Individuals in the ERICA 
study were linked with UK National Health Services 
(NHS) electronic healthcare records (ie, hospital episode 
statistics (HES) data are a database that includes details of 
all hospital admissions, accident and emergency depart-
ment visits and outpatient appointments at an individual 
patient level)22 and Office for National Statistics death 
data through anonymised identifications provided by the 
NHS.
Clinical measures
After 4 hours of fasting, with no bronchodilators for 6 
hours, and 10 minutes of supine rest, carotid–femoral 
aPWV and AIx measurements were taken using a Sphyg-
moCor system as previously described.23 CIMT of the 
common carotid arteries was measured using B- mode 
ultrasound at a distance of 1 cm from the carotid bulb 
with a linear probe of 7–12 MHz.24 The thickest artery 
of the two was included in the analysis. Fasting blood 
samples were taken for biochemical analysis, including 
plasma fibrinogen, serum CRP and glucose. Physical 
performance measures 6MWT25 and 4MGS26 were 
assessed according to guidelines. Diabetes status and 
antihypertensive treatment were self- reported at base-
line study visit. Disease severity was defined according to 
GOLD classification.20 Points for the BODE Index were 
assigned as described by Celli et al.27
CV hospitalisation and mortality
CV hospitalisation and mortality data were extracted 
from the linked hospital admission data and death certif-
icates. Non- fatal CV episodes were extracted from both 
primary and secondary International Statistical Classi-
fication of Diseases and Related Health Problems, 10th 
Revision (ICD-10) coding positions. Causes of death were 
adjudicated by CV and pulmonary physicians. We defined 
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the primary outcome as first reported occurrence (since 
study enrolment) of fatal or non- fatal hospitalised CVD, 
where CVD was defined as disease of the arteries, stroke or 
heart failure (see online supplemental table 1) based on 
classifications used by the Emerging Risk Factors Collab-
oration.28 Time to primary outcome was calculated from 
the difference between the baseline visit date (starting 
December 2011) and either the date of death or first 
hospitalised CV attendance up to November 2017, when 
follow- up discontinued. Secondary outcomes of interest 
were all- cause and cause- specific mortality (defined as CV, 
pulmonary, cancer or other).
Risk factors of interest
Conventional CVD risk factors included age, sex, self- 
reported smoking status (current/ex- smoker), high- 
density lipoprotein (HDL) cholesterol, total cholesterol, 
systolic blood pressure (SBP), diabetes (yes/no) and treat-
ment for high blood pressure (yes/no). We also assessed 
the addition of the following risk factors: BMI, aPWV 
and CIMT, fasting glucose, CRP and fibrinogen, COPD 
severity (ie, GOLD stage and BODE Index) and measures 
of physical performance (ie, 6MWT and 4MGS).
Statistical analysis
HRs with 95% CIs were estimated using Cox regres-
sion models stratified by study centre. Age and sex were 
added to all models. To quantify the independent asso-
ciation of CIMT, we further included SBP. For aPWV, we 
also included mean arterial pressure and resting heart 
rate. For AIx, we additionally included resting heart 
rate and height. Proportional hazards were assessed by 
Schoenfeld’s global tests. We assessed the relationships 
of the new markers and outcomes and consequently 
log- transformed the following risk factors: CRP, fibrin-
ogen and glucose. HRs for log- transformed risk factors 
represented a twofold increase in the risk factor, whereas 
others were presented as a change in unit. We evalu-
ated the predictive value of new markers added to the 
conventional CVD risk factors using measures of discrim-
ination (ie, Harrell’s C- statistic)29 30 and calibration 
(ie, Gronnesby and Borgan test and Brier score). The 
Gronnesby and Borgan test is an overall calibration test 
for Cox models based on grouping individuals by their 
estimated risk score and compares observed and model- 
based expected events within each group (a p value of 
>α suggests no difference). Brier scores range from 0 to 
1 (0 is perfect accuracy and 1 is perfect inaccuracy) and 
allow comparison of performance of a model with a refer-
ence model. The C- statistic is a measure for validating the 
discriminative ability of a model. Values range from 0.5 to 
1.0 (1.0 is a perfect prediction and 0.5 is a random guess). 
A higher score indicates better discriminative ability of 
the model. To optimise efficiency and to avoid opti-
mism from internal validation in small samples, we used 
10- fold cross validation with 200 replications31 (see online 
supplemental text 1 and online supplemental figures 1–5 
for further statistical analyses details).
Observational data are reported according to the 
Strengthening the Reporting of Observational Studies in 
Epidemiology statement.32 All tests were two- sided and 
statistical significance was defined by 95% CI for HRs 
not traversing 1 or p<0.05. Our analyses were performed 
using STATA V.13 and R (R Foundation).
RESULTS
Of the 729 individuals included in the study, 714 (98%) 
could be linked with hospital admission and survival 
records, and were included in the analysis (online supple-
mental figure 6). The median age was 67 (IQR 62–73) 
years, and 434 (61%) individuals were male (table 1). A 
third (n=218) of the cohort smoked; 12% (n=82) had 
self- reported diabetes; 34% (n=245) were taking antihy-
pertensive medications; and 31% (n=224) were taking 
cholesterol- lowering medications at baseline. The median 
FEV1 was 1.3 L (0.9–1.7 L) (mean±SD=1.34±0.53). In 
total, 192 individuals (27%) had a first event of CV hospi-
talisation (peripheral arterial disease (n=9), diseases of 
Table 1 Baseline characteristics (N=714)
Characteristics Summary measures
Conventional CVD risk factors
  Age (years) 67 (62–73)
  Male 434 (61)
  Current smoker 218 (31)
  HDL (mmol/L) 1.4 (1.2–1.7)
  Cholesterol (mmol/L) 5.0 (4.3–5.8)
  SBP (mm Hg) 142 (131–154)
  Diabetes mellitus 82 (12)
  Drugs to treat hypertension 245 (34)
CV measures
  aPWV (m/s) 9.8 (8.4–11.8)
  CIMT (mm) 0.81 (0.71–0.96)
Alternative measures
  CRP (mg/L) 1.21 (0.47–2.01)
  Fibrinogen (g/dL) 1.22 (1.06–1.36)
  Glucose (mmol/L) 1.59 (1.46–4.59)
  BMI (kg/m2) 27 (23–31)
  GOLD (stage) 2 (2–3)
  4MGS (m/s) 0.95 (0.77–1.14)
  6MWT distance (m) 366 (255–440)
  BODE (point) 3 (1–5)
Values are given as median and IQR, or number of cases (%).
aPWV, aortic pulse wave velocity; BMI, body mass index; BODE, 
Body mass index, airflow Obstruction, Dyspnoea and Exercise 
capacity; CIMT, carotid intima−media thickness; CRP, C reactive 
protein; CV, cardiovascular; CVD, cardiovascular disease; GOLD, 
Global Initiative for Chronic Obstructive Lung Disease; HDL, high- 
density lipoprotein; 4MGS, 4 m gait speed; 6MWT, 6 min walk test; 
SBP, systolic blood pressure.
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arteries, arterioles and capillaries (n=7), angina (n=21), 
unstable angina (n=3), coronary heart disease not other-
wise specified (n=63), acute myocardial infarction (MI) 
and certain current complications following acute MI 
(n=11), cerebral infarction (n=11), stroke, not specified 
as haemorrhage or infarction (n=3), other stroke (n=18), 
heart failure (n=32) and abdominal aortic aneurysm 
(n=8); n=116 (60%) were in ICD-10 secondary coding 
position) during median follow- up for 4.6 years, and 6 indi-
viduals had CV death without any preceding CV episode. 
CV hospitalisation accounted for the majority (97%) of 
events analysed. The CV incidence rate was 6.7 (95% CI 
5.8 to 7.7) per 100 person- years (see online supplemental 
tables 1 and 2) for categorisation of different admission 
codes for CV hospitalisation.
Conventional CVD risk factors
Of the conventional CVD risk factors, age and treat-
ment for high blood pressure had significant positive 
associations with the study’s outcome, whereas SBP had 
a significant negative association and other risk factors 
(ie, sex, smoking status, cholesterol, HDL cholesterol 
and diabetes) were not significantly associated with CV 
hospitalisation. Use of hypertension drug treatment 
followed by age and total cholesterol contributed most 
to the discriminative ability of the model. The overall 
discriminative ability of the CV risk model had a C- sta-
tistic of 0.689 (95% CI 0.688 to 0.691, figure 1 and online 
supplemental table 3).
Surrogate CV risk markers
Except for AIx, neither aPWV nor CIMT was significantly 
associated with CV hospitalisation after including conven-
tional CVD risk factors (figure 2 and online supplemental 
table 4). Moreover, none of the CV risk markers signifi-
cantly changed the discriminative ability of the CV risk 
model.
Physical performance measures, COPD severity and 
inflammatory markers
Multivariable analysis identified that poor physical perfor-
mance (ie, reduced 6MWT distance and slower 4MGS) 
was significantly associated with increased CV hospital-
isation, independently of conventional CVD risk factors. 
With the exception of glucose and BMI, severity of COPD 
defined by higher BODE Index and GOLD stage, as well 
Figure 1 Conventional CVD risk factors at baseline, their HRs and discriminative ability for fatal or non- fatal hospitalised 
CVD. Values are given as median and IQR, or number of cases (%). Baseline data of 714 patients are included. All models are 
stratified by recruitment site. There were <5% missing values for descriptive variables such as body mass index and smoking 
status. Missing values were addressed using multiple imputations using chained equations. aModel includes age and sex. 
bModel includes conventional CVD risk factors: age, sex, smoking, HDL, total cholesterol, SBP, diabetes and hypertension 
medication. CVD, cardiovascular disease; HDL, high- density lipoprotein; SBP, systolic blood pressure.
Figure 2 Aortic stiffness at baseline, their HRs and discriminative ability for fatal or non- fatal hospitalised CVD. Values are 
given as median and IQR, or number of cases (%). Baseline data of 714 patients are included. All models are stratified by 
recruitment site. Gronnesby and Borgan goodness of fit (χ2(3), p>χ2): CV risk model (2.07, 0.559), aPWV (1.64, 0.652), CIMT 
(2.32, 0.509), and AIx (3.08, 0.380). Estimates based on quartiles of risk. Brier score: CV risk model 0.129 (95% CI 0.111 to 
0.146), aPWV 0.126 (95% CI 0.108 to 0.145), CIMT 0.128 (95% CI 0.110 to 0.147) and AIx 0.126 (95% CI 0.109 to 0.144). Lower 
score indicates better accuracy of estimates. aModel includes age and sex. bModel includes conventional CVD risk factors: age, 
sex, smoking, high- density lipoprotein, total cholesterol, SBP, diabetes and hypertension medication. CIMT further included 
SBP. Carotid–femoral aPWV further included mean arterial pressure and resting heart rate. AIx further included resting heart rate 
and height. There were about 10% missing values for variables CIMT (n=66) and aPWV (n=60). Missing values were addressed 
using multiple imputations using chained equations. AIx, Augmentation Index; aPWV, aortic pulse wave velocity; CIMT, carotid 
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as inflammatory markers (ie, CRP and fibrinogen), all 
had significant positive associations with CV hospitalisa-
tions independently of conventional CVD risk factors.
Predictive modelling indicated significant improve-
ment in risk discrimination when adding BMI (C=0.698, 
95% CI 0.696 to 0.699), BODE (C=0.705, 95% CI 0.704 to 
0.707), 4MGS (C=0.712, 95% CI 0.710 to 0.713) or 6MWT 
(C=0.727, 95% CI 0.726 to 0.728) to the CV risk model, 
but not GOLD stage, inflammatory markers or glucose 
(figure 3 and online supplemental table 5). Calibration 
tests indicate good model fit (figures 2 and 3). Adding 
BMI, 4MGS, 6MWT and BODE collectively to the CV risk 
model resulted in a C- statistic of 0.731 (95% CI 0.729 
to 0.732), indicating 6MWT primarily accounted for 
improved discriminative ability of the model. The model 
including 6MWT had a better Brier score relative to the 
CV risk model (0.123 vs 0.129, respectively).
All-cause and cause-specific mortality
There were 144 deaths in total (nearly 20% of the 
cohort) over a median follow- up period of 4.6 years. 
The majority of deaths were in men (n=96, 67%), and 
pulmonary disease was the leading cause in both sexes 
(table 2). Pulmonary disease accounted for 65% of deaths 
in women and 50% in men, followed by cancer (19% in 
women, 27% in men), CV (6% and 16%) and other (10% 
and 7% in women and men, respectively).
DISCUSSION
This is the first study assessing the utility of conventional 
CVD risk factors for CV risk prediction and the value 
of additional markers of risk within a COPD cohort. 
Novel findings include (1) poor physical performance 
improved the discriminative power when added to the 
CV risk model; (2) BODE Index, GOLD stage, 4MGS and 
systemic inflammatory markers were positively associated 
with CV hospitalisations independently of conventional 
CVD risk factors, although they collectively improved 
the model’s discriminative ability marginally; and (3) of 
the conventional CVD risk factors, age, SBP and use of 
antihypertensives were positively associated with study 
outcome. However, age, cholesterol and use of antihy-
pertensives contributed most to the model’s prognostic 
power. SBP had a significant negative association with CV 
hospitalisations but did not add to the model’s predictive 
ability. Furthermore, aPWV and CIMT, despite providing 
in vivo mechanistic information about the arterial system, 
had no significant association with CV hospitalisations, 
whereas AIx did. Therefore, these data suggest that 
in COPD, physical performance (assessed by 6MWT) 
contributes to CV risk estimation defined predominantly 
Figure 3 Alternative measures at baseline, their HRs and discriminative ability for fatal or non- fatal hospitalised CVD. Values 
are given as median and IQR, or number of cases (%). Baseline data of 714 patients are included. All models are stratified by 
recruitment site. Gronnesby and Borgan goodness of fit (χ2(3), p>χ2): CV risk model (2.07, 0.559); CRP (0.32, 0.956); fibrinogen 
(1.48, 0.687); glucose (0.42, 0.936); BMI (1.56, 0.668); GOLD (5.63, 0.131); 4MGS (4.70, 0.195); 6MWT (2.94, 0.401); BODE 
(6.46, 0.091); BMI, 4MGS, 6MWT, bode (4.12, 0.249). Estimates based on quartiles of risk. Brier score: CV risk model 0.129 
(95% CI 0.111 to 0.146); CRP 0.125 (95% CI 0.107 to 0.142); fibrinogen 0.128 (95% CI 0.111 to 0.146); glucose 0.128 (95% CI 
0.111 to 0.146); BMI 0.128 (95% CI 0.111 to 0.146); GOLD 0.128 (95% CI 0.110 to 0.146); 4MGS 0.127 (95% CI 0.110 to 0.144); 
6MWT 0.123 (95% CI 0.105 to 0.140); BODE 0.124 (95% CI 0.106 to 0.142); BMI, 4MGS, 6MWT, BODE 0.122 (95% CI 0.104 to 
0.140). Lower score indicates better accuracy of estimates. aModel includes age and sex. bModel includes conventional CVD 
risk factors: age, sex, smoking, high- density lipoprotein, total cholesterol, systolic blood pressure, diabetes and hypertension 
medication. There were <5% missing values for biochemical markers, including fibrinogen and cholesterol. Missing values 
were addressed using multiple imputations using chained equations. 4MGS, 4 m gait speed; 6MWT, 6 min walk test; BMI, 
body mass index; BODE, Body mass index, airflow Obstruction, Dyspnoea, and Exercise capacity; CRP, C reactive protein; CV, 
cardiovascular; CVD, cardiovascular disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
Table 2 Mortality in the Evaluation of the Role of 









Pulmonary 31 (65) 48 (50) 79 (55)
Cardiovascular 3 (6) 15 (16) 18 (13)
Cancer 9 (19) 26 (27) 35 (24)
Other 5 (10) 7 (7) 12 (8)
All- cause 48 (100) 96 (100) 144 (100)
Deaths recorded over a median follow- up of 4.6 years.
 on D
ecem









pen: first published as 10.1136/bm






6 Fermont JM, et al. BMJ Open 2020;10:e038360. doi:10.1136/bmjopen-2020-038360
Open access 
by non- fatal CV hospitalisations. Finally, CVD contributed 
to only a small number of deaths at a median follow- up 
of 4.6 years. Pulmonary disease, followed by cancer, was 
the major cause of death in both men and women with 
COPD.
We observed a C- statistic of 0.689 based on the conven-
tional CV risk model, which increased to a maximum of 
0.731 when adding additional markers; this increment 
was primarily due to 6MWT. These C- statistic values indi-
cate a moderate predictive ability of the models for the 
study’s outcome. For perspective, a C- statistic of 0.53 was 
observed in a Framingham model in the very elderly 
(aged 85- plus years; the median age of our cohort was 67 
years) without prior CVD, indicating it does not predict 
CV mortality in this group.6 However, in primary care 
individuals without CVD in the Framingham study, a C- sta-
tistic of 0.76 for an outcome of general CVD (ie, coronary 
heart disease, stroke, peripheral artery disease or heart 
failure) demonstrated good discrimination.10 Since our 
cohort included individuals with CVD at baseline, and 
different CVD risk factors and CV outcomes are eval-
uated in various studies, no direct comparison of study 
results can be made. That aPWV was not predictive in our 
cohort contrasts with findings reported by Ben- Shlomo et 
al. However, from the 17 included cohorts in their study, 
none were COPD cohorts; the mean age of the cohorts 
was lower; and the proportion of individuals taking drugs 
to treat hypertension was higher.14
Overall, our study emphasises the importance of phys-
ical function as a predictor of CV risk. Tests such as 6MWT 
or 4MGS are proxy measures of overall mobility and phys-
ical functioning.33 Exercise capacity and CV fitness are 
known to be associated with fatal and non- fatal CVD,34 
while exercise- based cardiac rehabilitation reduces risk of 
CV events.35 The 6MWT distance is prognostic in patients 
with stable coronary heart disease12 and in those with 
moderate- to- severe heart failure.36
In our cohort, poor physical function improved discrim-
inative ability of the CV risk model beyond conventional 
CVD factors. This has implications for clinical practice in 
CV risk assessment for individuals with COPD, suggesting 
it may be helpful to incorporate physical performance into 
clinical assessment. Especially those aged under 65 years 
may benefit most from active CVD assessment, according 
to Morgan et al.37 However, given that 6MWT can be logis-
tically challenging to set up and time- consuming,38 the 
faster and simpler 4MGS that also significantly improved 
the C- statistic could be used as a simpler alternative. 
In elderly with CVD, 4MGS is comparable to 6MWT in 
predicting all- cause mortality.39
The BODE Index also significantly improved the C- sta-
tistic of the CV risk model. However, this was primarily 
due to the 6MWT component. In fact, although GOLD 
stage had a significant positive association with the study 
outcome, this did not improve the prognostic power of 
the model. Therefore, despite the association between 
airflow limitation and CV risk in general population 
studies,17 40 in patients with COPD, physical performance 
assessment rather than another component of BODE (ie, 
spirometry) adds value to CV risk prediction.
Although we did not find an association between 
inflammatory markers and surrogate markers of CV risk 
in the baseline cross- sectional component of the ERICA 
study,41 both CRP and fibrinogen were associated with CV 
hospitalisations captured over nearly 5 years of follow- up. 
That the associations remained significant after including 
conventional CVD risk factors indicates potential value 
for identifying high- risk individuals within a COPD popu-
lation. The inverse relationship of SBP was an unexpected 
finding. One hypothesis is that SBP has a J- shaped curve 
for CV events and mortality.42 Therefore, in this cohort, 
lower SBP might be a marker of sickness and frailty, hence 
its association with CV hospitalisations.
A third of the cohort had a CV- related hospitalisation 
during follow- up, and the majority had pre- existing CV 
comorbidity at baseline. The high numbers of CV hospi-
talisations give perspective of what this comorbidity incurs 
for patients and the huge healthcare costs involved. In 
contrast to the sizeable number of CV hospitalisations 
was the small number of CV deaths. Gayle et al previ-
ously reported that CV- related mortality in patients with 
chronic lung disease had already started to decline in 
England.43 This may reflect better CV risk management 
reducing CV mortality. Importantly though, such risk 
management does not seem to impact CV morbidity and 
is an area that requires future research to determine the 
optimum approach to impact CV morbidity in individuals 
with COPD.
Nearly 20% of the cohort died during follow- up. This 
is comparable to the TOwards a Revolution in COPD 
Health (TORCH) study where approximately 15% of 
the cohort died over 3 years of follow- up.2 Pulmonary 
disease, followed by cancer, accounted for proportion-
ally more deaths in our cohort compared with TORCH, 
whereas CV- specific mortality was less (10%–15% vs 27% 
in TORCH). Reasons for these findings are not entirely 
understood, but the sizeable proportion of our cohort 
already on medicines for dyslipidaemia and blood pres-
sure control may be an important factor.
Our study has limitations. The conventional CVD 
risk factors are usually used to predict CV risk defined 
by development of CVD. However, the majority of our 
participants already had CVD and were on CV medica-
tions, which may be a confounding factor impacting the 
discriminative ability of CVD risk factors. Moreover, in 
our study, CV risk was defined differently (as CV hospital-
isation with CV mortality). Hospitalised CV episodes were 
coded based on ICD-10 classifications28 extracted from 
both primary and secondary positions. Notably, most CV 
hospitalisations were recorded in secondary positions, 
indicating that the primary admission might be related 
to something else. Due to the few CV events recorded 
in the primary position, we were unable to conduct a 
sensitivity analysis including CV events in the primary 
position only. The study period covered the time from 
study enrolment until the end of study or death. Some 
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individuals, however, may have been admitted to hospital 
for CV events before study enrolment. We were unable 
to obtain HES data outside this period. Competing risks 
may have occurred, for example, individuals who died of 
other causes may not have experienced a CV event during 
the study period for this reason. However, our study did 
not have sufficient statistical power to assess this. It is 
possible our models predict non- CV hospitalisation due 
to, for example, potential cross- contamination of COPD 
and CV hospitalisation as a result of misclassification 
of morbidity and mortality that often occurs when data 
are obtained from routine sources.44 Deprivation scores 
may be another important determinant of CV risk in 
individuals with COPD that is worth evaluating in future 
research,45 although the relatively small cohort size of our 
study meant we did not include this in the analysis.
Furthermore, follow- up time for the study was a 
maximum of 5 years, whereas risk scores such as Fram-
ingham Risk Score and QRISK calculate a 10- year risk. 
Hence, the prognostic value of variables may alter with 
a different time horizon and depends on the extent of 
time trends in the new biomarkers. For example, a too 
short time period may result in an insufficient number 
of events, while over a longer time period, for example, 
20 years, the predictive ability would diminish because 
ageing is a strong predictor. We did not have access to an 
independent validation cohort but used cross- validation 
techniques instead. Generalisability of our results is 
limited to those with moderate COPD in the UK with 
NHS hospitalisations.
CONCLUSION
In a UK COPD cohort, poor physical performance assessed 
by 6MWT or 4MGS and inflammatory biomarkers are asso-
ciated with subsequent CV- related hospitalisations, inde-
pendently of conventional CVD risk factors. Importantly, 
poor physical performance (defined primarily by 6MWT) 
also significantly improved the predictive discrimination 
of the CV risk model. These data suggest an assessment of 
physical performance may enhance CV risk evaluation in 
individuals with COPD.
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Supplementary text 
Text 1 Supplementary methods 
There were missing values. Data were assessed for the level and type of missing data, and 
completion patterns (Figures 1-2). There were about 10% missing values for variables CIMT (n 
= 66) and PWV (n = 60), with <5% missing values for other variables (Figures 3-5). Missing 
values were addressed using multiple imputations using chained equations (MICE). The time-
to-event outcome was included using the non-parametric Nelson-Aalen estimator. Predictive 
mean matching was used for continuous variables, ordered logistic regression (as continuous) 
for ordinal variables, multinomial logistic regression for categorical variables, and logistic 
regression for binary variables. Derived variables such as the BODE Index (a composite score 
of BMI, forced expiratory volume in one second (FEV1), Medical Research Council dyspnoea 
score, and 6MWT distance) and GOLD stage were estimated post MICE using passive 
imputation. 
 
Data were cleaned for episode status, and inpatient (i.e. hospitalised) CV episodes were 
identified based on classifications used by the Emerging Risk Factors Collaboration.1 
Cardiovascular events were extracted from both primary and secondary positions of ICD-10. 
Priority was given to CV events reported in the primary position (n = 70). Following this, we 
selected CV events in the secondary position (n = 116), which had no recording of a CV event 
in the primary position. Only episodes during the study follow-up were evaluated.
                                                        
1 The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in 
over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol 22, 839–869 
(2007). https://doi.org/10.1007/s10654-007-9165-7 
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Supplementary tables 
Table 1 Definitions of diagnoses by ICD-10 coding. 
End point ICD-10 codes 
All cardiovascular disease F01, G46.3-G46.7, G458, G459 
I11.0, I13.0, I13.2, I20.0-I20.1, I20.8-I25, 
I50, I60, I61, I.62, I63, I64, I65-I69, I70.2, 
I71.3-I71.9, I72, I73.9-I79 + cardiac death 
Diseases of the arteries I70.2, I72, I73.9-I79 
Peripheral arterial disease I70.2, I73.9 
Diseases of arteries, arterioles and 
capillaries 
I72, I74-I79 
Coronary heart disease I20.0-I20.1, I20.8-I25 
Angina I20.1, I20.8-I20.9 
Unstable angina I20.0, I24 
Coronary heart disease not otherwise 
specified 
I25 
Acute myocardial infarction (MI), and certain 
current complications following acute MI 
I21, I23 
Subsequent myocardial infarction I22 
All stroke I60, I61, I.62, I63, I64, I65-I69, F01, G46.3-
G46.7, G458, G459 
Subarachnoid haemorrhage I60 
Intra-cerebral haemorrhage I61 
Cerebral infarction I63 
Stroke, not specified as haemorrhage or 
infarction 
I64 
Stroke syndromes G46.3-G46.7 
Transient ischemic attack G458, G459 
Other stroke I62, I65-I69, F01 
Heart failure I11.0, I13.0, I13.2, I50 
Heart failure I50 
Hypertensive heart disease with 
(congestive) heart failure 
I11.0 
Hypertensive heart and renal disease with 
(congestive) heart failure 
I13.0 
Hypertensive heart and renal disease with 
both (congestive) heart failure and renal 
disease 
I13.2 
Cardiac death Adjudicated 
Other vascular deaths I71.3-I71.9 
Abdominal aortic aneurysm I71.3-I71.9 
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Table 2 Fatal or non-fatal hospitalised cardiovascular disease by ICD-10 
coding position. 















1 I714   J441  
2 I209   J441  
3 I501     
4 I771   J440  
5 I251     
6 I251     
7 I219    J440 
8 I251     
9 I745     
10 I259     
11 I251   J441  
12 I251     
13 I500   J440  
14 I743   J441  
15 I64X   J440  
16 I714     
17 I219   J440  
18 I211     
19 I64X     
20 I739     
21 I739     
22 I639     
23 I251   J441  
24 I652     
25 I251   J440  
26 I251     
27 I632     
28 I251   J440  
29 I660   J440  
30 I500   J441  
31 I771     
32 I251   J441  
33 I638   J441  
34 I702   J440  
35 I200   J441  
36 I652     
37 I501   J441  
38 I214     
39 I64X   J440  
40 I509     
41 I739     
42 I739     
43 I639    J440 
44 I743     
45 I251     
46 I251   J440  
47 I219     
48 I638     
49 I251   J440  
50 I251   J440  
51 I639    J440 
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52 I500     
53 I251     
54 I251   J441  
55 I639     
56 I652    J440 
57 I219     
58 I635     
59 I214   J440  
60 I251     
61 I739    J440 
62 I639     
63 I251   J440  
64 I200    J440 
65 I214    J440 
66 I251     
67 I634    J440 
68 I209    J440 
69 I714     
70 I509     
71  I209  J440  
72  I501    
73  I713   J440 
74  I714    
75  I252   J440 
76  I259  J440  
77  I252  J440  
78  I500  J441  
79  I694    
80  I209    
81  I209    
82  I259  J441  
83  I509  J440  
84  I500   J440 
85  I509   J440 
86  I200    
87  I219  J440  
88  I714   J440 
89  I780   J440 
90  I219  J440  
91  I252  J440  
92  I714  J441  
93  I209   J440 
94  I251  J440  
95  I259   J440 
96  I501  J440  
97  I252    
98  I252    
99  I500   J440 
100  I252   J440 
101  I252    
102  I652    
103  I500  J440  
104  I259  J441  
105  I251    
106  I501  J440  
107  I252    
108  I255   J440 
109  I259   J440 
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110  I500  J440  
111  I252    
112  I252  J440  
113  I259    
114  I678  J441  
115  I501   J440 
116  I678  J440  
117  I501   J440 
118  I678  J440  
119  I259    
120  I209    
121  I209  J441  
122  I500  J441  
123  I259   J440 
124  I259   J440 
125  I259   J440 
126  I209  J440  
127  I252   J440 
128  I509  J440  
129  I209    
130  I259    
131  I259    
132  I259  J440  
133  I209    
134  I679    
135  I678  J440  
136  I500  J440  
137  I501    
138  I500  J441  
139  I209    
140  I652  J440  
141  I209    
142  I678    
143  I209    
144  I209  J441  
145  I501  J441  
146  I209  J440  
147  I209  J440  
148  I739    
149  I509    
150  I678  J441  
151  I252  J440  
152  I252    
153  I501  J440  
154  I678    
155  I251  J440  
156  I252   J440 
157  I500  J440  
158  I252  J440  
159  I252  J440  
160  I634    
161  I679    
162  I252  J440  
163  I252    
164  I500   J440 
165  I209  J441  
166  I739   J440 
167  I739  J440  
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168  I259    
169  I509   J440 
170  I252    
171  I209   J440 
172  I798  J440  
173  I500    
174  I209    
175  I501  J440  
176  I219  J441  
177  I209    
178  I252  J440  
179  I252    
180  I671  J441  
181  I259    
182  I259  J440  
183  I671    
184  I259   J440 
185  I251   J440 
186  I714   J440 
187   Cardiac   
188   Cardiac   
189   Cardiac   
190   Cardiac   
191   Cardiac   
192   Cardiac   
Total 
recorded 
70 116 6 74 35 
Twenty-five individuals with a CV event recorded in the primary position also had an acute exacerbation of COPD 
(AECOPD) recorded in the primary position during the study period. In addition, 49 individuals with a CV event 
recorded in the secondary position also had an AECOPD recorded in the primary position during the study period.
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Table 3 Conventional cardiovascular disease risk factors at baseline, their hazard ratios for cardiovascular disease. 
 Median (IQR) or No. (%) HR (95% CI)a P value HR (95% CI)b P value 
Conventional CVD risk factors      
Age – per 10 year increase 67 (62-73) 1.58 (1.30 to 1.92) < 0.001 1.59 (1.29 to 1.99) < 0.001 
Sex – males 434 (61) 1.28 (0.94 to 1.74) 0.113 1.16 (0.84 to 1.60) 0.375 
Smoking – current 218 (31) 0.95 (0.68 to 1.31) 0.744 0.92 (0.66 to 1.29) 0.632 
HDL – per 1 mmol/L increase 1.4 (1.2-1.7) 0.73 (0.52 to 1.03) 0.074 0.86 (0.60 to 1.23) 0.402 
Total cholesterol – per 1 mmol/L increase 5.0 (4.3-5.8) 0.80 (0.70 to 0.92) 0.002 0.89 (0.76 to 1.03) 0.118 
SBP – per 10 mmHg increase 142 (131-154) 0.91 (0.84 to 0.99) 0.023 0.90 (0.82 to 0.98) 0.016 
Diabetes – yes 82 (12) 1.50 (1.01 to 2.22) 0.044 1.15 (0.76 to 1.75) 0.511 
Hypertension treatment  – yes 245 (34) 1.79 (1.34 to 2.38) < 0.001 1.76 (1.31 to 2.36) < 0.001 
Values are given as the median and interquartile range (IQR), or No. of cases (%). Baseline data of 714 patients are included. All models are stratified by recruitment site. 
aModel includes age and sex. 
bModel includes conventional cardiovascular disease risk factors: age, sex, smoking, high-density lipoprotein, total cholesterol, systolic blood pressure, diabetes, hypertension drug treatment. 
CI = confidence interval. HDL = high-density lipoprotein. SBP = systolic blood pressure. CV = cardiovascular. 
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Table 4 Arterial stiffness at baseline, their hazard ratios for cardiovascular disease. 
 Median (IQR) or No. (%) HR (95% CI)a P value HR (95% CI)b P value 
Measures of arterial 
stiffness 
     
PWV – per 1 m/sec increase 9.8 (8.4-11.8) 1.01 (0.95 to 1.07) 0.796 0.99 (0.93 to 1.06) 0.749 
CIMT – per 1 mm increase 0.81 (0.71-0.96) 1.09 (0.49 to 2.45) 0.827 1.08 (0.48 to 2.43) 0.861 
AIx – per 5% increase 28 (20-34) 0.85 (0.77 to 0.93) < 0.001 0.90 (0.82 to 0.99) 0.027 
Values are given as the median and interquartile range (IQR), or No. of cases (%). Baseline data of 714 patients are included. All models are stratified by recruitment site. 
aModel includes age and sex. 
bModel includes conventional cardiovascular disease risk factors: age, sex, smoking, high-density lipoprotein, total cholesterol, systolic blood pressure, diabetes, hypertension drug treatment. 
Carotid intima-media thickness further included systolic blood pressure. Carotid-femoral aortic pulse wave velocity further included mean arterial pressure and resting heart rate. AIx further included 
resting heart rate and height.  
CI = confidence interval. PWV = pulse wave velocity. CIMT = carotid intima-media thickness. AIx = augmentation index. 
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-038360:e038360. 10 2020;BMJ Open, et al. Fermont JM
 10 
Table 5 Alternative measures at baseline, their hazard ratios for cardiovascular disease. 
 Median (IQR) or No. (%) HR (95% CI)a P value HR (95% CI)b P value 
Other risk factors      
CRP – per twofold increase 1.21 (0.47 to 2.01) 1.22 (1.07 to 1.39) 0.002 1.20 (1.06 to 1.37) 0.005 
Fibrinogen – per twofold increase 1.22 (1.06 to 1.36) 2.27 (1.20 to 4.31) 0.012 2.12 (1.10 to 4.07) 0.024 
Glucose – per twofold increase 1.59 (1.50 to 1.69) 1.18 (0.46 to 2.99) 0.730 0.83 (0.32 to 2.18) 0.709 
BMI – per 1 kg/m2 increase 27 (23-31) 1.04 (1.01 to 1.06) 0.002 1.02 (0.99 to 1.05) 0.089 
GOLD – per 1 stage increase 1 (1-2) 1.22 (0.98 to 1.52) 0.071 1.29 (1.03 to 1.61) 0.026 
4MGST – per 1 second increase 4.2 (3.5 to 5.2) 1.09 (1.03 to 1.16) 0.002 1.07 (1.01 to 1.14) 0.020 
6MWT distance – per 30 metre increase 366 (255 to 440) 0.91 (0.88 to 0.94) < 0.001 0.91 (0.88 to 0.95) < 0.001 
BODE – per 1 point increase 3 (1-5) 1.13 (1.07 to 1.20) < 0.001 1.15 (1.08 to 1.21) < 0.001 
Values are given as the median and interquartile range (IQR), or No. of cases (%). Baseline data of 714 patients are included. All models are stratified by recruitment site. 
aModel includes age and sex. 
bModel includes conventional cardiovascular disease risk factors: age, sex, smoking, high-density lipoprotein, total cholesterol, systolic blood pressure, diabetes, hypertension drug treatment. 
CI = confidence interval. CRP = C-reactive protein. BMI = body mass index. GOLD = global initiative for chronic obstructive lung disease. 4MGS = four-metre gait speed. 6MWT = six-minute walk test. 
BODE = body mass index, obstruction, dyspnoea, exercise. 
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Figure 3 Differences in baseline pulse wave velocity. 
Histograms displaying the distribution of PWV by sex and recruitment site. Dashed lines indicate median values by 




Figure 4 Differences in baseline carotid intima-media thickness. 
Histograms displaying the distribution of CIMT by sex and recruitment site. Dashed lines indicate median values by 
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Figure 5 Differences in baseline augmentation index. 
Histograms displaying the distribution of AIx by sex and recruitment site. Dashed lines indicate median values by sex. 
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Figure 6 Participant enrolment flow diagram with five years follow up. 
Total number of CV events (n = 192): peripheral arterial disease (n = 9), diseases of arteries, arterioles and capillaries 
(n = 7), angina (n = 21), unstable angina (n = 3), coronary heart disease not otherwise specified (n = 63), acute 
myocardial infarction (MI), and certain current complications following acute MI (n = 11), cerebral infarction (n = 11), 
stroke, not specified as haemorrhage or infarction (n = 3), other stroke (n = 18), heart failure (n = 32), abdominal aortic 
aneurysm (n = 8), and cardiac death (n = 6). FEV1 = forced expiratory volume one second. FVC = forced vital capacity. 
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